Enzymatica to commence clinical market-monitoring study for the prevention and shortening of upper airway infection

Enzymatica’s “COLDPREV” study will commence during the spring. The study – which is placebo controlled – is aimed at investigating the prevention and disease progression in subjects who become inoculated (infected) with the common cold virus.

Enzymatica has received approval from the Regional Ethical Review Board in Lund for its ”COLDPREV” clinical study. The study is a randomized, double-blind, and placebo controlled market-monitoring investigation for the CE marked medical device product, ColdZyme® Mouth Spray. The purpose of the study is to deepen knowledge about the prevention and shortening of the disease progression in upper airway infections.

“Looked at from a wider perspective, effective treatment using ColdZyme could prove beneficial for people who are particularly sensitive to colds. Reducing the risk for users of contracting a cold or shortening the period of illness may also offer societal benefits in terms of reduced absenteeism” notes Mats Clarsund, EVP,  Research and Development, at Enzymatica

ColdZyme® Mouth Spray, which is a CE marked medical device for the European market, has intended use to reduce the risk of contracting a cold or shortening the period of illness at an early stage by creating a protective barrier in the oral cavity and throat. The product was registered with the Swedish MPA as a medical device product, Class I in August 2012.The sale of ColdZyme® Mouth Spray will commence in pharmacies nationwide in Sweden in early February 2013.

For more information on the COLDPREV study, contact:
Mats Clarsund, EVP, Research and Development, Enzymatica AB (publ), 0733-46 34 29
mats.clarsund@enzymatica.se

For more information about Enzymatica, contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ), 0768-14 41 66,
michael.christensen@enzymatica.se

Tags: